Articles from PHARMANEST

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis

Companies to use AI-enabled digital pathology and spatial single-fiber analysis to characterize the mechanistic effects of MTX-474 in systemic sclerosis

By PHARMANEST · Via ACCESS Newswire · September 30, 2026